AGAP2 and hepatocellular carcinoma: In line with this result, Tao et al.13 have affirmed that AGAP2-AS1 expression in serum exosomes is higher than in exosomes-depleted serum from NSCLC patients, and exosomal miR-296 has been revealed to down-regulate in hepatocellular carcinoma cells16.